AERI has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
AERI has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Aerie Pharmaceuticals's quarterly accounts payable & accrued expense increased from Mar. 2022 ($99.0 Mil) to Jun. 2022 ($101.8 Mil) and increased from Jun. 2022 ($101.8 Mil) to Sep. 2022 ($116.7 Mil).
Aerie Pharmaceuticals's annual accounts payable & accrued expense increased from Dec. 2019 ($67.0 Mil) to Dec. 2020 ($84.3 Mil) and increased from Dec. 2020 ($84.3 Mil) to Dec. 2021 ($104.7 Mil).
The historical data trend for Aerie Pharmaceuticals's Accounts Payable & Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aerie Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Accounts Payable & Accrued Expense | Get a 7-Day Free Trial | 17.30 | 40.35 | 66.98 | 84.34 | 104.75 |
Aerie Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
Accounts Payable & Accrued Expense | Get a 7-Day Free Trial | 99.61 | 104.75 | 98.97 | 101.82 | 116.72 |
Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.
Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.
It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.
Peter Frederick Lang | officer: Chief Financial Officer | AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703 |
Raj Kannan | director, officer: Chief Executive Officer | C/O CHIASMA, INC. 460 TOTTEN POND RD, SUITE 530, WALTHAM MA 02451 |
Jeffrey Calabrese | officer: Vice President of Finance | AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703 |
Kathleen Mcginley | officer: CHRO & VP, Corp Services | 15279 ALTON PARKWAY SUITE 100, IRVINE CA 92618 |
Christopher Staten | officer: Interim CFO | AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BOULEVARD, SUITE 400, DURHAM NC 27703 |
Casey C. Kopczynski | officer: Chief Scientific Officer | 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921 |
Peter J Mcdonnell | director | 2525 DUPONT DRIVE, IRVINE CA 92612 |
Gerald D. Cagle | director | 135 U.S. HIGHWAY 206, SUITE 15, BEDMINSTER NJ 07921 |
Foresite Capital Fund Ii, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
David Hollander | officer: Chief R&D Officer | C/O AERIE PHARMACEUTICALS, INC., 4301 EMPEROR BLVD., SUITE 400, DURHAM NC 27703 |
Richard J Rubino | officer: Chief Financial Officer | |
Vicente Jr Anido | director, officer: Chief Executive Officer | 1621 BAYSIDE DR, CORONA DEL MAR CA 92625 |
Foresite Capital Management Iv, Llc | 10 percent owner | 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939 |
Foresite Capital Fund Iv, L.p. | 10 percent owner | 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111 |
Thomas A Mitro | officer: President and COO | 15279 ALTON PARKWAY SUITE #100, IRVINE CA 92618 |
From GuruFocus
By Business Wire Business Wire • 07-08-2022
By PRNewswire PRNewswire • 10-25-2022
By Business Wire Business Wire • 08-25-2022
By Business Wire Business Wire • 07-28-2022
By Business Wire Business Wire • 04-06-2022
By Business Wire Business Wire • 10-14-2022
By Business Wire Business Wire • 03-18-2022
By PurpleRose PurpleRose • 08-25-2022
By Business Wire Business Wire • 02-17-2022
By GuruFocus Research GuruFocus Editor • 01-27-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.